Casirivimab/imdevimab
Antiviral combination medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Casirivimab/imdevimab?
Summarize this article for a 10 year old
Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others,[8][10] is a combination medicine used for the treatment and prevention of COVID‑19.[10] It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection.[12][8][10] The combination of two antibodies is intended to prevent mutational escape.[13] It is also available as a co-formulated product.[12] It was developed by the American biotechnology company Regeneron Pharmaceuticals.[14][15]
Combination of | |
---|---|
Casirivimab | Monoclonal antibody against spike protein of SARS-CoV-2 |
Imdevimab | Monoclonal antibody against spike protein of SARS-CoV-2 |
Clinical data | |
Trade names | REGEN-COV, Ronapreve |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620063 |
License data |
|
Pregnancy category | |
Routes of administration | Intravenous, subcutaneous injection |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
DrugBank | |
KEGG |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Spike protein of SARS-CoV-2 |
Clinical data | |
Other names | REGN10933 |
ATC code |
|
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Spike protein of SARS-CoV-2 |
Clinical data | |
Other names | REGN10987 |
ATC code |
|
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG |
The most common side effects include allergic reactions, which include infusion related reactions, injection site reactions,[10] brief pain, weakness and others.[16]
The combination is approved under the brand name Ronapreve for medical use in Japan, the United Kingdom, the European Union, and Australia.[1][7][10][11][17][18]
In January 2022, the U.S. Food and Drug Administration (FDA) revised the authorizations for two monoclonal antibody treatments – bamlanivimab/etesevimab (administered together) and casirivimab/imdevimab – to limit their use to only when the recipients are likely to have been infected with or exposed to a variant that is susceptible to these treatments because data show these treatments are highly unlikely to be active against the omicron variant.[19]